Document is current
Any future updates will be listed below
-
Authors
Xu, Chong
Mei, Yilan
Yang, Ruihan
Luo, Qiudan
Zhang, Jienian
Kou, Xiaolin
Hu, Jianfeng
Wang, Yujie
Li, Yue
Chen, Rong
Zhang, Zhengping
Yao, Yuyuan
Sima, Jian https://orcid.org/0000-0002-4127-1638
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82173804, 82001144)
High-Level Talents Start-up Funding of China Pharmaceutical University (3150120042)
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 5 April 2024
First Online: 27 April 2024
Declarations
:
: All experiments were conducted in accordance with the regulations for the Administration of Affairs Concerning Experimental Animals and approved by the Laboratory Animal Care Committee at the China Pharmaceutical University (Permit number SYXK-2021-0011).
: All the listed authors have participated in the study, and have seen and approved the submitted manuscript.
: A related patent has been authorized in the United States (US11135199B2). Assignees: NeuroDawn Pharmaceuticals Co. Ltd; Simcere Pharmaceuticals Co. Ltd. No authors in this article were listed on the patent. No funds were received related to the patent. The authors declare that they have no conflicts of interest with the contents of this article.
